Behavioral and neurochemical effects of alpha-lipoic acid in the model of parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  De Araújo, Dayane Pessoa ^a   De Sousa, Caren Nádia Soares ^a   Araújo, Paulo Victor Pontes ^a   Menezes, Carlos Eduardo De Souza ^a   Sousa Rodrigues, Francisca Taciana ^a   Escudeiro, Sarah Souza ^a   Lima, Nicole Brito Cortez ^b   Patrocínio, Manoel Claúdio Azevedo ^b   Aguiar, Lissiana Magna Vasconcelos ^a   Viana, Glauce Socorro De Barros ^a   Vasconcelos, Silvânia Maria Mendes ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Faculty of Medicine Christus   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CATALASE; LEVODOPA; LIPID; NITRITE; OXIDOPAMINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOCTIC ACID;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY MOVEMENT; CONTROLLED STUDY; CORPUS STRIATUM; CYLINDER TEST; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME ACTIVITY; LIPID PEROXIDATION; LOCOMOTION; MALE; MOTOR PERFORMANCE; NEUROCHEMISTRY; NEUROLOGIC EXAMINATION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 84884235932     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/571378     Document Type: Article

References (69)

1. Teive H. A. G., Pathogenesis of Parkinson's disease. Reviews Neuroscience 2005 13 201 214
2. Fekete R., Jankovic J., Revisiting the relationship between essential tremor and Parkinson's disease. Movement Disorders 2011 26 3 391 398 2-s2.0-79953287466 10.1002/mds.23512
3. Aguiar L. M., Nobre H. V. Jr., Macêdo D. S., Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacology Biochemistry & Behavior 2006 84 3 415 419
4. Jenner P., In Principles of Treatment in Parkinson's Disease 2005 Philadelphia, Pa, USA Elsevier
5. Xu K., Bastia E., Schwarzschild M. A., Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacology and Therapeutics 2005 105 3 267 310 2-s2.0-14544288232 10.1016/j.pharmthera.2004.10.007
6. Holloway R. G., Shoulson I., Fahn S., Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of Neurology 2004 61 7 1044 1053 2-s2.0-3142733662 10.1001/archneur.61.7.1044
7. Rodrigues M., Campos L. C., Tegy for treatment with levodopa in Parkinson's disease. Revista Analytica 2006 5 23 121 129
8. Araujo D. P., Lobato R. F. G., Cavalcanti J. R. L., The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of parkinson's disease: a review. International Journal of Neuroscience 2011 121 2 51 57
9. Ferreira P. M. P., Militão G. C. G., Freitas R. M., Lipoic acid effects on lipid peroxidation level, superoxide dismutase activity and monoamines concentration in rat hippocampus. Neuroscience Letters 2009 464 2 131 134 2-s2.0-69549088653 10.1016/j.neulet.2009.08.051
10. Bist R., Bhatt D. K., The evaluation of effect of alpha-lipoic acid and vitamin E on the lipid peroxidation, gamma-amino butyric acid and serotonin level in the brain of mice (Mus musculus) acutely intoxicated with lindane. Journal of the Neurological Sciences 2009 276 1-2 99 102 2-s2.0-58149174089 10.1016/j.jns.2008.09.008
11. Bilska A., Dubiel M., Sokołowska-Jezewicz M., Lorenc-Koci E., Włodek L., Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 2007 146 4 1758 1771 2-s2.0-34249039316 10.1016/j.neuroscience. 2007.04.002
12. Archer J., Tests for emotionality in rats and mice: a review. Animal Behaviour 1973 21 2 205 235 2-s2.0-0015837338
13. Schallert T., Fleming S. M., Leasure J. L., Tillerson J. L., Bland S. T., CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000 39 5 777 787 2-s2.0-0033950675 10.1016/S0028-3908(00) 00005-8
14. Draper H. H., Hadley M., Malondialdehyde determination as index of lipid peroxidation. Methods in Enzymology 1990 186 421 431 10.1016/0076-6879(90)86135- I
15. Green L. C., Tannenbaum S. R., Goldman P., Nitrate synthesis in the germfree and conventional rat. Science 1981 212 4490 56 58 10.1126/science. 6451927
16. Maehly A. C., Chance B., The assay of catalases and peroxidases. Methods Biochemical Analysis 1954 1 357 424 10.1002/9780470110171.ch14
17. Salazar M. R., Alpha lipoic acid: a novel treatment for depression. Medical Hypotheses 2000 55 6 510 512 2-s2.0-0033638674 10.1054/mehy.2000.1103
18. Fujita H., Shiosaka M., Ogino T., Okimura Y., Utsumi T., Sato E. F., Akagi R., Inoue M., Utsumi K., Sasaki J., α -Lipoic acid suppresses 6-hydroxydopamine-induced ROS generation and apoptosis through the stimulation of glutathione synthesis but not by the expression of heme oxygenase-1. Brain Research 2008 1206 1 12 2-s2.0-41649114315 10.1016/j.brainres.2008.01.081
19. Rosini M., Simoni E., Bartolini M., Tarozzi A., Matera R., Milelli A., Hrelia P., Andrisano V., Bolognesi M. L., Melchiorre C., Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. European Journal of Medicinal Chemistry 2011 46 11 5435 5442 2-s2.0-80054960254 10.1016/j.ejmech.2011.09.001
20. Mythri R. B., Srinivas Bharath M. M., Curcumin: a potential neuroprotective agent in Parkinson's disease. Current Pharmaceutical Design 2012 18 1 91 99 2-s2.0-84855858783 10.2174/138161212798918995
21. Albarracin S. L., Stab B., Casas Z., Sutachan J. J., Samudio I., Gonzalez J., Gonzalo L., Capani F., Morales L., Barreto G. E., Effects of natural antioxidants in neurodegenerative disease. Nutritional Neuroscience 2012 15 1 1 9 2-s2.0-84856729444 10.1179/1476830511Y.0000000028
22. Connell B. J., Khan B. V., Rajagopal D., Saleh T. M., Novel neurovascular protective agents: effects of INV-155, INV-157, INV-159, and INV-161 versus lipoic acid and captopril in a rat stroke model. Cardiology Research and Practice 2012 2012 6 2-s2.0-84856593301 10.1155/2012/319230 319230
23. Ilse S. P., Bingwei L., Timothy S., Closing the gap between clinic and cage: sensori-motor and cognitive behavioural testing regimens in neurotoxin-induced animal models of Parkinson's disease. Neuroscience & Biobehavioral Reviews 2012 36 10 2305 2324
24. Dauer W., Przedborski S., Parkinson's disease: mechanisms and models. Neuron 2003 39 6 889 909 2-s2.0-0141741347 10.1016/S0896-6273(03)00568-3
25. Ungerstedt U., Arbuthnott G. W., Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Research 1970 24 3 485 493 2-s2.0-0014954436
26. Iancu R., Mohapel P., Brundin P., Paul G., Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behavioural Brain Research 2005 162 1 1 10 2-s2.0-19444370500 10.1016/j.bbr.2005.02.023
27. Graham D. G., Tiffany S. M., Bell W. R. Jr., Gutknecht W. F., Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Molecular Pharmacology 1978 14 4 644 653 2-s2.0-0018148688
28. Cohen G., Heikkila R. E., The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6 hydroxydopamine, dialuric acid, and related cytotoxic agents. Journal of Biological Chemistry 1974 249 8 2447 2452 2-s2.0-0016378870
29. Bové J., Perier C., Neurotoxin-based models of Parkinson's disease. Neuroscience 2012 211 51 76 2-s2.0-84860615324 10.1016/j.neuroscience. 2011.10.057
30. Glinka Y., Gassen M., Youdim M. B. H., Mechanism of 6-hydroxydopamine neurotoxicity. Journal of Neural Transmission, Supplement 1997 50 55 66 2-s2.0-0030614642
31. 2a: Uma Nova Perspectiva Para o tratamento da Doença de Parkinson 2009 Fortaleza, Brazil Universidade Federal do Ceará
32. Lazzaretti C., Fatores interferentes na indução da atividade rotacional induzida pelo teste de motricidade sobre a grade em modelo animal de parkinson 2011 Rio Grande do Sul, Brazil Universidade Federal Do Rio Grande do Sul
33. Dooley C. T., Li L., Misler J. A., Thompson J. H., Toxicity of 6-hydroxydopamine: live cell imaging of cytoplasmic redox flux. Cell Biology and Toxicology 2012 28 2 89 101 2-s2.0-84859164120 10.1007/s10565-011-9209-3
34. Jalali-Nadoushan M., Roghani M., Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Research 2013 1505 68 74
35. Zaitone S. A., Abo-Elmatty D. M., Shaalan A. A., Acetyl-l-carnitine and α -lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacology Biochemistry and Behavior 2012 100 3 347 360 2-s2.0-80053943300 10.1016/j.pbb.2011.09.002
36. Jouve L., Salin P., Melon C., Kerkerian-Le Goff L., Deep brain stimulation of the center median-parafascicular complex of the thalamus has efficient anti-Parkinsonian action associated with widespread cellular responses in the basal ganglia network in a rat model of Parkinson's Disease. Journal of Neuroscience 2010 30 29 9919 9928 2-s2.0-77954842853 10.1523/JNEUROSCI.1404-10. 2010
37. Juliet M. T., Main B. S., Crack P. J., Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochemistry International 2013 62 5 803 819
38. Weinreb O., Mandel S., Youdim M. B. H., Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radical Biology and Medicine 2013 62 52 64 10.1016/j.freeradbiomed.2013.01.017
39. Zhang Q. J., Li L. B., Niu X. L., Liu J., Gui Z. H., Feng J. J., Ali U., Hui Y. P., Wu Z. H., The pyramidal neurons in the medial prefrontal cortex show decreased response to 5-hydroxytryptamine-3 receptor stimulation in a rodent model of Parkinson's disease. Brain Research 2011 1384 69 79 2-s2.0-79953028130 10.1016/j.brainres.2011.01.086
40. Ferreira I. C. R. F., Abreu R. M. V., Oxidative stress, antioxidants and phytochemicals. Bioanálise 2007 4 12 18
41. Clayton C. C., Almeida A. B., Araújo P. V., Oxidative stress and epilepsy: literature review. Oxidative Medicine and Cellular Longevity 2012 2012 12 795259 10.1155/2012/795259
42. Ferro M. M., Caracterização neuroquímica e comportamental da lesão da via nigroestriatal com 1-metil-4-fenil-1, 2, 3, 6-tetraidropiridina (MPTP) e 6-hidroxidopamine (6-OHDA) em ratos 2007 Santa Catarina, Brazil
43. Matsumoto Y., Murakami H., Hattori N., Yoshimoto K., Asano S., Inden M., Excessive expression of hippocampal Ezrin is induced by intrastriatal injection of 6-hydroxydopamine. Biological and Pharmaceutical Bulletin 2011 34 11 1753 1758 2-s2.0-81455149032 10.1248/bpb.34.1753
44. Barbosa M. T., Caramelli P., Maia D. P., Parkinsonism and parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Movement Disorders 2006 21 6 800 808
45. Dexter D. T., Peter J., Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology and Medicine 2013 62 132 144
46. di Stefano A., Sozio P., Cocco A., Iannitelli A., Santucci E., Costa M., Pecci L., Nasuti C., Cantalamessa F., Pinnen F., L-Dopa- and dopamine-(R)- α -lipoic acid conjugates as multifunctional codrugs with antioxidant properties. Journal of Medicinal Chemistry 2006 49 4 1486 1493 2-s2.0-33144480459 10.1021/jm051145p
47. Lipski J., Nistico R., Berretta N., Guatteo E., Bernardi G., Mercuri N. B., L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? Progress in Neurobiology 2011 94 4 389 407 2-s2.0-79960244516 10.1016/j.pneurobio.2011.06.005
48. Kang K. S., Yamabe N., Wen Y., Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration. Brain Research 2013 1497 1 1425
49. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreira M., Naini A. B., Fahn S., Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Annals of Neurology 1993 34 5 715 723 2-s2.0-0027487511 10.1002/ana.410340515
50. Miller R. L., James-Kracke M., Sun G. Y., Oxidative and inflammatory pathways in parkinson's disease. Neurochemical Research 2009 34 1 55 65
51. Abdin A. A., Sarhan N. I., Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α -lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity. Neuroscience Research 2011 71 4 387 395 2-s2.0-81055140360 10.1016/j.neures.2011.08.008
52. Guatteo E., Yee A., McKearney J., Dual effects of l-DOPA on nigral dopaminergic neurons. Experimental Neurology 2013 10.1016/j.expneurol.2013.02. 009
53. Aizenman E., White W. F., Loring R. H., Rosenberg P. A., A 3,4-dihydroxyphenylalanine oxidation product is a non-N-methyl-D-aspartate glutamatergic agonist in rat cortical neurons. Neuroscience Letters 1990 116 1-2 168 171 2-s2.0-0025283271 10.1016/0304-3940(90)90404-W
54. Newcomer T. A., Rosenberg P. A., Aizenman E., Iron-mediated oxidation of 3,4-dihydroxyphenylalanine to an excitotoxin. Journal of Neurochemistry 1995 64 4 1742 1748 2-s2.0-0028988351
55. Rosenberg P. A., Loring R., Xie Y., Zaleskas V., Aizenman E., 2,4,5-Trihydroxyphenylalanine in solution forms a non-N-methyl- D-aspartate glutamatergic agonist and neurotoxin. Proceedings of the National Academy of Sciences of the United States of America 1991 88 11 4865 4869 2-s2.0-0025805548
56. Yamamoto S., Takahashi N., Mori Y., Chemical physiology of oxidative stress-activated TRPM2 and TRPC5 channels. Progress in Biophysics and Molecular Biology 2010 103 1 18 27 2-s2.0-77955266662 10.1016/j.pbiomolbio.2010.05.005
57. Chung K. K. H., Freestone P. S., Lipski J., Expression and functional properties of TRPM2 channels in dopaminergic neurons of the substantia nigra of the rat. Journal of Neurophysiology 2011 106 6 2865 2875 2-s2.0-83055186788 10.1152/jn.00994.2010
58. Yuan H., Zhang Z. W., Zhang L. W., Treatment strategies for Parkinson's disease. Neuroscience Bulletin 2010 26 1 66 76
59. Miller R. L., James-Kracke M., Sun G. Y., Sun A. Y., Oxidative and inflammatory pathways in parkinson's disease. Neurochemical Research 2009 34 1 55 65 2-s2.0-58149466868 10.1007/s11064-008-9656-2
60. Wang X., Yu Y., Ji L., Liang X., Zhang T., Hai C.-X., Alpha-lipoic acid protects against myocardial ischemia/reperfusion injury via multiple target effects. Food and Chemical Toxicology 2011 49 11 2750 2757 2-s2.0-80052823577 10.1016/j.fct.2011.07.065
61. Astiz M., María, de Alaniz J. T., Marra C. A., The oxidative damage and inflammation caused by pesticides are reverted by lipoic acid in rat brain. Neurochemistry International 2012 61 7 1231 1241
62. Santos Í. M. D. S., de Freitas R. L. M., Saldanha G. B., Tomé A. D. R., Jordán J., de Freitas R. M., Alterations on monoamines concentration in rat hippocampus produced by lipoic acid. Arquivos de Neuro-Psiquiatria 2010 68 3 362 366 2-s2.0-77954568197
63. Kaki S. S., Grey C., Adlercreutz P., Bioorganic synthesis, characterization and antioxidant activity of esters of natural phenolics and α -lipoic acid. Journal of Biotechnology 2012 157 2 344 349 2-s2.0-84855676090 10.1016/j.jbiotec.2011.11.012
64. Gora̧ca A., Huk-Kolega H., Piechota A., Kleniewska P., Ciejka E., Skibska B., Lipoic acid-biological activity and therapeutic potential. Pharmacological Reports 2011 63 4 849 858 2-s2.0-80053351784
65. Soto-Otero R., Méndez-Álvarez E., Hermida-Ameijeiras Á., Muñoz-Patiño A. M., Labandeira-Garcia J. L., Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. Journal of Neurochemistry 2000 74 4 1605 1612 2-s2.0-0342369569 10.1046/j.1471-4159.2000.0741605.x
66. Chorilli M., Radicais livres e antioxidantes: conceitos fundamentais para aplicação em formulações farmacêuticas e cosméticas. Revista Brasileira de Ciências Farmacêuticas 2007 88 113 118
67. Biewenga G. P., Haenen G. R. M., Bast A., The pharmacology of the antioxidante lipoic acid. General Pharmaceuticals 1997 29 3 315 331
68. Silva M. C., Sousa C. N., Sampaio L. R., Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression? Archives of Pharmacology 2013 386 8 685 895 10.1007/s00210-013-0867- y
69. Bush A. J., Metal complexing agents as therapies for Alzheimer's disease. Neurobiology of Aging 2002 23 6 1031 1038 2-s2.0-0036860349 10.1016/S0197-4580(02)00120-3